Primary Care Clinical Trials (PCCT) performs a wide variety of clinical research studies under the auspices of the Department of Family and Community Medicine at Thomas Jefferson University. The department’s clinical practice provides care to more than 40,000 patients, a diverse population which is representative of the greater Philadelphia metropolitan area, who make approximately 80,000 outpatient visits per year. Our experienced research staff includes full-time Faculty, Clinical Fellows, a Clinical Research Nurse, research assistants and other administrative professionals. The PCCT’s clinical trials focus on the prevention and management of chronic diseases.
Clinical Vaccine Trials
Clinical vaccine trials are being conducted in a variety of departments throughout Jefferson.
Primary Care Clinical Trials
Christopher V. Chambers, MD, Director
Lori Conley, RN, Coordinator
HIV Clinical Trials
Department of Medicine
Division of Infectious Diseases
HIV Clinical Trials Unit
Kathleen E. Squires, MD, Director
Gwen Verlinghieri, RN, Coordinator
The HIV Clinical Trials Unit (CTU) conducts clinical research studies to define optimal management strategies for the treatment of HIV infection and related opportunistic infections and/or complications through an NIH-funded network, the AIDS Clinical Trials Group, and collaborations with the pharmaceutical industry. The Jefferson University Physicians HIV clinic care to more than 600 patients.
In the News
New Funding for JVC Members
Dr. McGettigan, was awarded a four-year $1.5 million R01 grant from the NIH to extend his exciting work on the development of a novel, safe, and effective rabies virus vaccine.
A Team of Researchers from Fox Chase, Jefferson and Penn State Receive NIAID Grant for Viral Control. Both Dr. Luis Sigal and Dr. Eisenlohr are members of the JVC. The team to receive a total of approximately $2 million each year for the next five years. For more information ...
Dr. David Abraham received a five year R01 grant to study the development of a recombinant vaccine against human onchocerciasis.